Clinical Trial Update: An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy [Phase 4]

View source ↗

Summary

Open-label Phase 4 trial evaluating 48-week Peginterferon alfa-2a for sustained response in chronic hepatitis B patients with HBeAg seroconversion on nucleoside…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Chronic Hepaititis B | Phase 4 | Status: COMPLETED